Meridian Bioscience, Inc. announced that it has received FDA clearance from the US Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT! CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the US. Approximately 20 million stool culture tests are conducted each year in the US to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact.
There is a real need for the ImmunoCard STAT! CAMPY because of its simplified, easy to perform procedure that provides patient results in 20 minutes. In addition, ImmunoCard STAT! CAMPY provides a solution to several concerns associated with culture testing, currently the most commonly practiced lab technique for detecting the Campylobacter bacteria. With culture, there is a potential for reduction in sensitivity due to variable culturing procedures, specimen viability, and inhibitory antibiotics in culture media. ImmunoCard STAT! CAMPY dramatically reduces these concerns with a consistent method that measures the bacterial antigen instead of measuring the viability of this fragile bacteria in an environment that is less inhibitory than current culturing procedures.
John A. Kraeutler, Chief Executive Officer, stated, “ImmunoCard STAT! CAMPY is a significant addition to our foodborne category because it provides laboratories with a rapid, accurate and easy to perform platform for the detection of Campylobacter. This innovative assay, along with Meridian’s Premier CAMPY and toxigenic E. coli tests, demonstrates Meridian’s emerging leadership in foodborne testing. ImmunoCard STAT! CAMPY is already in distribution by Meridian Bioscience Europe for the company’s European markets and was also recently approved for sale in Canada.”